isosorbide dinitrate
isosorbide dinitrate structure
|
Common Name | isosorbide dinitrate | ||
|---|---|---|---|---|
| CAS Number | 87-33-2 | Molecular Weight | 236.136 | |
| Density | 1.7±0.1 g/cm3 | Boiling Point | 365.9±42.0 °C at 760 mmHg | |
| Molecular Formula | C6H8N2O8 | Melting Point | 700C | |
| MSDS | N/A | Flash Point | 186.6±29.9 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
In vitro and in vivo evaluation of novel osmotic pump tablets of isosorbide-5-mononitrate containing polyvinyl pyrrolidone (PVP) for controlled release.
Pharmazie 67(8) , 695-700, (2012) A novel osmotic pump tablet with ethyl cellulose (EC) and polyvinyl pyrrolidone (PVP) as the semipermeable membrane and isosorbide-5-mononitrate (5-ISMN) as the model drug was formulated in this study. Zero order release kinetics were attained by avoiding agi... |
|
|
Superoxide dismutases, SOD1 and SOD2, play a distinct role in the fat body during pupation in silkworm Bombyx mori.
PLoS ONE 10(2) , e0116007, (2015) One way that aerobic biological systems counteract the generation of reactive oxygen species (ROS) is with superoxide dismutase proteins SOD1 and SOD2 that metabolize superoxide radicals to molecular oxygen and hydrogen peroxide or scavenge oxygen radicals pr... |
|
|
Early administration of isosorbide dinitrate improves survival of cyanide-poisoned rabbits.
Clin. Toxicol. (Phila.) 53(1) , 22-7, (2015) More effective, rapidly delivered, safer antidotes are needed for cyanide poisoning. Previous study has demonstrated a beneficial effect of isosorbide dinitrate on the survival of cyanide-poisoned mice.To evaluate the effectiveness of isosorbide dinitrate com... |
|
|
Headache response to nitrate in patients with coronary artery disease and systolic heart failure
Int. J. Cardiol. 158(3) , 453-4, (2012)
|
|
|
A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer.
Ann. Oncol. 23(11) , 2925-30, (2012) We investigated the efficacy of irinotecan/cisplatin (IP) versus irinotecan/capecitabine (IX) with or without isosorbide-5-mononitrate (ISMN) in chemo-naïve advanced non-small-cell lung cancer.Initially, 74 patients were randomly assigned to either IP or IX. ... |
|
|
Role of isosorbide dinitrate in management of chronic congestive heart failure.
Am. Heart J. 110(1 Pt 2) , 264-8, (1985) Congestive heart failure is accompanied by a number of compensatory mechanisms that may overshoot the mark. Among these are excessive arteriolar and venous constriction. Nitrates are effective in producing venodilation, redistributing blood from the chest to ... |
|
|
A smoothing expectation and substitution algorithm for the semiparametric accelerated failure time frailty model.
Stat. Med. 31(21) , 2335-58, (2012) This paper proposes an estimation procedure for the semiparametric accelerated failure time frailty model that combines smoothing with an Expectation and Maximization-like algorithm for estimating equations. The resulting algorithm permits simultaneous estima... |
|
|
Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure.
Cleve. Clin. J. Med. 74(3) , 227-34, (2007) The African American Heart Failure Trial (A-HeFT) found that African American patients with advanced heart failure fared better if the fixed-dose combination of isosorbide dinitrate and hydralazine was added to their regimen, which for most of them already in... |
|
|
Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?
J. Law. Med. Ethics 36(3) , 458-63, (2008) Race is not a scientific category, but African Americans have increased prevalence and severity of heart failure. The African American Heart Failure trial showed the benefit of a combination of isosorbide dinitrate (a nitric oxide donor) and hydralazine (an a... |
|
|
Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure.
Expert Opin. Pharmacother. 7(18) , 2521-31, (2006) The major advances in our understanding and management of heart failure (HF) in recent decades have not fully benefited all segments of our population. HF still represents a growing epidemic, especially for African-Americans, in whom the burden of HF is even ... |